HIV病毒包膜蛋白gp120与卡介苗感染人巨噬细胞的实验研究

目的:比较研究HIV病毒包膜蛋白gp120与卡介苗分别及共同感染人巨噬细胞,对人巨噬细胞的破坏能力及诱导巨噬细胞产生一氧化氮(NO)能力的差异性.方法:gp120与卡介苗(BCG)分别及共同感染人巨噬细胞后,于不同时间点采用MTT法检测巨噬细胞存活率,利用硝酸还原酶法检测细胞培养上清液中NO的含量.结果:gp120与BCG分别及共同感染人巨噬细胞,均可降低巨噬细胞的存活率,但gp120与卡介苗共同感染巨噬细胞,其存活率降低更为显著(P＜0.05);gp120与BCG均可激活人巨噬细胞合成和释放NO,而gp120与BCG共同感染组激活人巨噬细胞合成和释放NO的量明显低于BCG感染组(P＜0.05).结论:gp120感染巨噬细胞可影响巨噬细胞抗微生物的活性,可增强卡介苗对巨噬细胞的破坏作用.     

抗HIV活性天然产物

自从1981年发现获得性免疫缺陷病(AIDS)起,一直受到科学界重视.对抗人免疫缺陷病毒(HIV)药物进行了大量的研究.本文综述最近抗HIV活性天然产物的研究进展.     

共同受体CCR5与HIV gp120的相互作用及相关肽类抑制剂

存在于巨嗜细胞、树突状细胞等胞膜上的G蛋白偶联受体CCR5作为R5嗜性的HIV-1病毒的主要共同受体,可以和病毒的表面糖蛋白gp120相互作用,并由此决定了病毒的另一表面糖蛋白gp41融合构象的形成以及随后的病毒与细胞的膜融合。CCR5在细胞膜上迅速移动,并与其他分子(如CD4和胆固醇)存在相互作用,加速了与gp120的作用。CCR5的这种中心作用已经使其成为抗HIV-1药物研究的很有吸引力的靶点。目前已发现一系列衍生于CCR5的胞外区的多肽、天然存在的蛋白质以及设计的多肽,可干扰CCR5与gp120之间的相互作用,从而抑制病毒复制。     

抗补体活性多糖

补体系统在宿主免疫中具有重要的作用。近年来,由某些中药中纯化的多糖具有明显的抗补体作用。这些多糖大多数含有阿拉伯糖、半乳糖和半乳糖醛酸,分子量范围6.000到500.000。它们的结构很复杂,多为具聚鼠李半乳糖醛酸结构中心的酸性杂多糖和果胶类多糖。这些多糖的抗补体活性可能和整个大分子的结构有关。一旦发生降解活性就大为下降甚至消失。它们都可以经典的方式激活补体系统。大部分也可以改变的方式激活补体系统。     

重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV-1表面糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1/3的gp120(包含gp120V1/V2抗原决定簇)有效表达,表达蛋白占菌体总蛋白的18%;Westernblot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

人星形细胞HIV—1膜蛋白gp120新受体的免疫学鉴定

自1994年首次报导HIV－1外膜蛋白gp120与人胎儿星形细胞膜蛋白质位点（推测分子量为260kD,命名为PAG）结合以来[1],这项工作持续集中于研究该蛋白的功能与作用,本研究藉助杂交瘤技术建立了一系列不鼠抗人星形细胞PAG）的单克隆抗体,这些抗体成功的抑制了gp120与PAG的结合,抑制可达50％以上,并几乎完全阻断了gp120介导的由摄入所星表细胞风钙离子的升高,通过ELISA可证实抗体与星形细胞的特异反应,蛋白印迹和免疫沉淀试验结果表明PAG作为实体的存在,试验表明PAG对于gp120与星形细胞的结合,对于gp120个导的星形细胞摄入所致钙离子的升高均有决定性作用,许多方向报导和研究表明gp120可与多种细胞结合而导致HIV－1感染,由此推论PAG是HIV－1gp120在人星形细胞上的新受体,同时也可能对HIV－1脑病的治疗开辟一条崭新的途径,PAG是否为HIV－1感染人星形细胞的受体,仍有等进一步实验证明。     

重组HIV表面抗原gp120的表达纯化及免疫学鉴定

为研制具有流行特点的HIV血清学诊断试剂,采用pET系统表达HIV－1表达糖蛋白gp120。研究发现,全长的gp120在E.coli中不能有效表达;N端半长的gp120可以表达,但表达量很低;仅保留N端1／3的gp120（包含gp120V1／V2抗决定簇）有效表达,表达蛋白占菌体总蛋白的18％;Western blot显示较好的反应原性;通过金属螯合层析,产物得到完全纯化。在这些结果的基础上,我们表达了流行株的gp120片段,为探索gp120在大肠杆菌的高效表达,建立针对中国人群的HIV血清学诊断系统奠定基础。     

HIV gp41基因分段低温诱导表达

人类免疫缺陷病毒(Human immunodeficiency virus,HIV)GP41跨膜蛋白由于具有特殊的穿膜拓扑结构,对宿主菌细胞膜产生毒性作用而使其难以在E.coli中有效表达[1].本室前期工作发现GP41蛋白中有三个区域对表达菌细胞具有毒性作用,其分别为:位于N端2/3区域(N3片段:nt7373-8006)的融合肽(aa512-527)和跨膜区(Aa 684-705),它们含有丰富的疏水性氨基酸;以及位于C端1/3区域(C片段:nt8007-8339)的慢病毒裂解肽LLP1(aa 826-854)和LLP2(aa 768-788),可形成2个两亲性α螺旋,从而对宿主菌产生较强的细胞膜毒性作用使细菌大量死亡,最终致使GP41蛋白难以获得有效表达[2].为此我们尝试在低温条件(16℃)下对HIV-gp41N端2/3和C端1/3区域在大肠杆菌BL21(DE)3中进行诱导表达,并对低温条件下GP41蛋白表达对细菌细胞膜的毒性作用特征进行初步探讨.     

The disulfide loop of gp41 is critical to the furin recognition site of HIV gp160

The importance of the HIV gp41 conserved disulfide loop to envelope function has been examined by mutational and functional analyses. Based on a luciferase-reporter entry assay, mutants gp41-CC/AA (C598A/C604A) and gp41-Delta (deletion of residues 596-606) result in a nonfunctional envelope protein. Western blot analysis shows both mutants to be properly expressed but not processed to form gp120 and gp41, which explains their nonfunctionality. The presence of mutant gp160 on the cell surface, as well as their ability to bind to sCD4, suggests that the mutations have disrupted processing at the furin recognition site encoded within the gp120 conserved domain 5, without resulting in an overall misfolding of the protein. With respect to the furin recognition site, the mutations are sequentially distant, which implies that the gp41 disulfide loop is interacting with gp120 C5 in gp160. In addition, we have modeled the gp120-gp41 interaction in unprocessed precursor gp160 using structural data available for gp120 and gp41 domains in isolation, supplemented by mutagenesis data. We suggest that the mutations have altered the interaction between gp120 C5 and the gp41 disulfide loop, resulting in decreased accessibility of the furin recognition site and implying that the interaction between the gp120 C5 and gp41 loop is a conformational requirement for gp160 processing. The sensitivity of this interaction could be exploited in future antivirals designed to disrupt HIV pathogenesis by disrupting gp160 processing.     

Triazine Dyes Inhibit HIV-1 Entry by Binding to Envelope Glycoproteins

We have attempted to purify envelope (Env) glycoproteins of human immunodeficiency virus (HIV) from the culture supernatants of CHO-Sec cells that secreted truncated 140-kDa precursor and mature 120-kDa Env glycoproteins. The concentrated culture supernatants were applied to a column coupled with cibacron blue 3GA (CB3GA) to separate albumin from the Env proteins because CB3GA, a triazine dye, has been known to have a high affinity to albumin. Unexpectedly, Env proteins as well as albumin bound to the column, and the bound Env proteins were eluted by increasing the ionic strength using KC1. Gp120 was eluted at 0.5–0.9 m of KC1, while a higher concentration (0.9–1.5 m ) was necessary for the elution of gp140. The agarose gel coupled with reactive red 120 (RR120), another triazine dye with similar characteristics, also retained both Env proteins, and the bound Env proteins could be eluted in a similar manner. In addition, these agents inhibited syncytium formation caused by HTLV-III_B and HTLV-II_MN. Inhibition was also seen when a virus-free fusion assay between Env protein expressed in CHO cells and fluorescent labeled SupT1 cells were used. These findings indicate that triazine dyes bind to the functional regions of Env proteins of HIV-1 that play important role(s) for HIV infection.     

Lack of gp120-induced anergy and apoptosis in chimpanzees is correlated with resistance to AIDS

Human immunodeficiency virus-1 (HIV-1) infects both humans and chimpanzees, but in the chimpanzee, HIV-1 infection leads only very rarely to loss of CD4 T cells or to AIDS-like disease. The pathogenetic basis for this difference in host range is not understood. In previous studies, using CD4 T cells from HIV-1 seronegative human donors, we demonstrated that crosslinking of CD4-bound gp120, followed by signaling through the T cell receptor for antigen (TCR), resulted in cell death by apoptosis. To determine whether activation-induced apoptosis correlates with progression to AIDS, we studied the chimpanzee. Our data suggest that, although human CD4 T cells respond to CD4 ligation with anergy and apoptosis upon activation, chimpanzee CD4 T cells do not undergo apoptosis after cross-linking of CD4-bound gp120, followed by signaling through the TCR. In addition, proliferation assays show that chimpanzee CD4 T cells do not become anergic after CD4 ligation. Thus, it is possible that, in the chimpanzee, the absence of cellular anergy and apoptotic cell death after CD4 ligation by HIV-1 gp120 protect this primate species from progression to AIDS-like disease.This investigation was supported by National Institute of Health grants AI-30575, AI-29903, AI-35513, and RR00015 (TH Finkel), AI-05060 (WC Satterfield), American Foundation for AIDS Research grants 02270-16-RG (TH Finkel) and 770188-11-PF (NK Banda), the Concerned Parents for AIDS Research, the UCHSC Cancer Center, the Eleanore and Michael Stobin Trust, and the Bender Foundation.     

Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies

Conventional antibodies react with antigens reversibly. We report the formation of unusually stable complexes of HIV gp120 and nucleophilic antibodies raised by immunization with an electrophilic HIV gp120 analog (E-gp120). The stability of the complexes was evident from their very slow dissociation in a nondenaturing solvent (approximate t(1/2) 18.5 days) and their resistance to dissociation by a denaturant commonly employed to disrupt noncovalent protein-protein binding (sodium dodecyl sulfate). Kinetic studies indicated time-dependent and virtually complete progression of the antibody-gp120 complexes from the initial noncovalent state to a poorly dissociable state. The antibodies to E-gp120 displayed improved covalent reactivity with an electrophilic phosphonate probe compared to control antibodies, suggesting their enhanced nucleophilicity. One of the stably binding antibodies neutralized the infectivity of CCR5-dependent primary HIV strains belonging to clades B and C. These findings suggest the feasibility of raising antibodies capable of long-lasting inactivation of antigens by electrophilic immunization.     

Detection of IgA-binding sites on human immunodeficiency virus type-1 envelope glycoproteins, Gp120 and Gp41

IgA has been supposed to play an important role in the prevention of HIV-1 infection. In this study, IgA-binding sites on gp120 and gp41 of HIV-1 envelope glycoproteins were analyzed using ELISA and overlapping synthetic peptides covering all of the gp120 and gp41 sites. IgA antibodies in plasma and saliva mainly bound to six and five sites on gp120 and gp41, respectively. Some of the IgA-binding sites differed from those of IgG-binding sites and the amount of IgA antibodies that bound to each site varied among samples. IgA antibodies in some plasma samples neutralized HIV-1 infection, and those IgA antibodies contained the antibodies which bound to the V3, C3 and ELDKWA sites. The results suggest that IgA antibodies which bind to certain sites on HIV-1 envelope glycoproteins may neutralize HIV-1 infection, presumably at mucosal sites where most IgA antibodies are produced. The induction of IgA antibodies that bind specific sites and neutralize HIV-1 infection at mucosal sites may be important in the development of a vaccine against HIV-1 infection.     

Linear epitope mapping of humoral responses induced by vaccination with recombinant HIV-1 envelope protein gp160

To enhance utility of the linear epitope mapping (Pepscan) technique for assay of humoral responses linked to vaccination, two modifications were tested. First, peptides were incubated with serum contained in baths rather than individual wells. Second, a rigorous statistical model was developed to determine which peptide/antibody-binding interactions were significant. The modifications increased the ability to detect signal in these experiments by 15- to 45-fold. These two modifications were applied to linear epitope mapping of HIV seropositive volunteers under treatment with recombinant HIV gp160 and also to rabbits immunized with the same product. Changes in fine specificity of response were observed in animal models and human vaccine recipients over the course of an immunization series with this antigen. Received 16 July 1996/ Accepted in revised form 09 April 1997     

Host-cell-specific glycosylation of HIV-2 envelope glycoprotein

Neutral complex-type N-glycans of the envelope glycoprotein 120 of HIV-2, propagated in different host cells, display cell-type specific variations. In order to identify typical structural elements, glycans were analysed by gel filtration, by enzymic sequencing and, in part, by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The characteristic substituents of di- tri- and tetraantennary carbohydrate units thus observed include N-acetyllactosamine repeats, bisecting N-acetylglucosamine and fucose linked to the chitobiose core as well as to N-acetyllactosamine antennae. Each glycoprotein preparation displayed a characteristic set of glycoforms. This revised version was published online in November 2006 with corrections to the Cover Date.     

Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs

Human immunodeficiency virus (HIV) entry into cells is initiated by the binding of its envelope glycoprotein (Env) gp120 to receptor CD4. Antibodies that bind to epitopes overlapping the CD4-binding site (CD4bs) on gp120 can prevent HIV entry by competing with cell-associated CD4; their ability to outcompete CD4 is a major determinant of their neutralizing potency and is proportional to their avidity. The breadth of neutralization and the likelihood of the emergence of antibody-resistant virus are critically dependent on the structure of their epitopes. Because CD4bs is highly conserved, it is reasonable to hypothesize that antibodies closely mimicking CD4 could exhibit relatively broad cross-reactivity and a high probability of preventing the emergence of resistant viruses. Previously, in a search for antibodies that mimic CD4 or the co-receptor, we identified and characterized a broadly cross-reactive HIV-neutralizing CD4bs human monoclonal antibody (hmAb), m18. Here, we describe the crystal structure of Fab m18 at 2.03 A resolution, which reveals unique conformations of heavy chain complementarity-determining regions (CDRs) 2 and 3 (H2 and H3). H2 is highly bulged and lacks cross-linking interstrand hydrogen bonds observed in all four canonical structures. H3 is 17.5 A long and rigid, forming an extended beta-sheet decorated with an alpha-turn motif bearing a phenylalanine-isoleucine fork at the apex. It shows striking similarity to the Ig CDR2-like C'C' region of the CD4 first domain D1 that dominates the binding of CD4 to gp120. Docking simulations suggest significant similarity between the m18 epitope and the CD4bs on gp120. Fab m18 does not enhance binding of CD4-induced (CD4i) antibodies, nor does it induce CD4-independent fusion mediated by the HIV Env. Thus, vaccine immunogens based on the m18 epitope structure are unlikely to elicit antibodies that could enhance infection. The structure can also serve as a basis for the design of novel, highly efficient inhibitors of HIV entry.     

Purification of L-Isoleucyl t-rna Synthetase by Affinity Chromatography

L-Isoleucyl t-RNA synthetase was purified to 97% purity in a single step by affinity chromatography on a column carrying L-isoleucinyl 5′-adenylate as the insolubilized ligand. Recovery was 50–60%.     

中国HIV-1流行毒株的DNA疫苗的初步研究

为研制针对我国ＨＩＶ－１流行毒株的艾滋病毒疫苗,构建了具有代表性的ｇａｇ和ｇｐ１２０核酸疫苗,进行了初步的小鼠免疫实验。结果初步显示：（１）免疫Ｂａｌｂ／Ｃ小鼠可以产生ＨＩＶ－１特异性的体液和细胞免疫;（２）ｇａｇ和ｇｐ１２０基因联合免疫可以同时诱发针对ｇａｇ和ｇｐ１２０的细胞和体液免疫反应,而且效果比各自单独免疫要好;（３）Ｂ亚型ｇｐ１２０基因免疫可以诱发识别Ｃ亚型ｇｐ１２０抗原的ＣＴＬ反应。本